Physician profile
Raisa Oklander
NPI 1164482097
$13,396.17
in general payments reported to CMS, 2019-2025
50 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,705 · 2021: $2,386 · 2022: $2,530 · 2023: $1,927 · 2024: $2,051 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,129.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,278.84 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,379.78 | 2019-2024 | Airsupra, Farxiga |
| Abbvie INC. | $1,309.64 | 2019-2025 | |
| Lilly USA, LLC | $796.40 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amneal Pharmaceuticals LLC | $764.61 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $686.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $555.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.86 | 2019-2025 | Jardiance |
| Dexcom, INC. | $488.75 | 2019-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $483.88 | 2024-2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $482.33 | 2020-2024 | Linzess |
| Sanofi-Aventis U.S. LLC | $448.26 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $245.99 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $227.38 | 2019-2021 | |
| Amgen INC. | $222.38 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $198.22 | 2019-2020 | |
| Amarin Pharma, INC. | $195.17 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $178.20 | 2021-2023 | |
| Horizon Therapeutics Plc | $160.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $139.15 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Aimmune Therapeutics, INC. | $131.90 | 2024-2025 | Zenpep |
| Amryt Pharma Holdings LTD | $130.66 | 2022-2023 | Mycapssa |
| Cequr Corporation | $124.09 | 2022-2025 | Cequr Simplicity |
| Kyowa Kirin, INC. | $112.11 | 2023-2025 | Crysvita |
| Currax Pharmaceuticals LLC | $110.76 | 2022-2025 | Contrave, Onzetra Xsail |
| Insulet Corporation | $107.08 | 2019-2022 | |
| Intuity Medical INC | $80.00 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbott Laboratories | $68.74 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $61.61 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Vistapharm, INC. | $59.70 | 2021 | |
| Chiesi USA, INC. | $55.53 | 2024-2025 | Mycapssa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.43 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.21 | 2023-2024 | Eliquis |
| Ardelyx, INC. | $52.87 | 2024-2025 | Ibsrela |
| Allergan, INC. | $51.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.25 | 2019-2020 | |
| Zealand Pharma US, INC. | $36.67 | 2021 | |
| Gilead Sciences, INC. | $34.21 | 2025 | |
| Merck Sharp & Dohme LLC | $34.13 | 2020-2021 | |
| Pfizer INC. | $33.16 | 2022-2024 | |
| Glaxosmithkline, LLC. | $26.25 | 2025 | Trelegy Ellipta |
| Theracosbio, LLC | $23.51 | 2024 | Brenzavvy |
| Vivus LLC | $22.31 | 2021 | |
| Avanir Pharmaceuticals, INC. | $21.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.73 | 2022 | |
| Lifescan, INC. | $20.00 | 2021 | |
| Echosens North America, INC. | $19.69 | 2019 | |
| Ibsa Pharma INC. | $18.56 | 2020 | |
| Boston Scientific Corporation | $16.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raisa Oklander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.